Please login to the form below

Mark Mallon

This page shows the latest Mark Mallon news and features for those working in and with pharma, biotech and healthcare.

Grünenthal buys Zomig rights as AZ slimming drive continues

Mark Mallon, EVP, global product and portfolio strategy at AstraZeneca, said: “Grünenthal is an established partner with expertise in the treatment of pain.

Latest news

AZ agrees to $320m deal for Zoladex

Mark Mallon, executive vice president of global product and portfolio strategy at AZ, said: “ This agreement allows us to retain a significant share of the value of Zoladex in the US
AstraZeneca sets sights on China with Takeda deal

The company's executive vice president, international - Mark Mallon - said the increased investment "reinforces our commitment to bring innovative medicines from our exciting pipeline of targeted and biological medicines to patients
AstraZeneca removes R&D and commercial heads

The regions covered are North America, Europe and international and are respectively filled by Paul Hudson, Ruud Dobber and Mark Mallon.
AstraZeneca signs IBS collaboration with Ironwood in China

treatment option,” said Mark Mallon, regional VP for Asia Pacific and president, AstraZeneca China.
AstraZeneca to buy Chinese generics firm

Mark Mallon, president of AstraZeneca's Asia-Pacific region, said: “ Our new acquisition further underscores our intention to serve the health needs of Chinese patients through our innovative medicines and, increasingly,

More from news
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest Intelligence

China: AstraZeneca’s new engine for growth and innovation

AstraZeneca’s Mark Mallon talks to PME about how its long-term investment in China is paying off. " /. ... Mark Mallon is one of the chief architects of AstraZeneca’s current success in China.
Made in China

Mark Mallon is executive vice president of Global Product &Portfolio Strategy at AstraZeneca, and before that spent many years as the company’s head of China and then the wider Asia ... AZ's Mark Mallon. “We have built the right culture there,

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Experienced Editor, London, Medical Communications: Competitive package

Project / Account Manager (Medical Education): Salary TBC

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Senior Medical Writer (Remote Working): Competitive Salary Offered

Account Director – Global Healthcare PR: Salary TBC

Director Healthcare PR Communications: Salary TBC

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Account Manager, Healthcare Advertising: Salary TBC

Associate Medical Director: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Associate Medical Director: Highly Competitive

Director – Head of Public Affairs: Neg

Senior Account Executive – Medical Communications: Salary TBC

Scientific Team Lead: Competitive Salary

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Editorial Director – Medical Education: Neg

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Scientific Director: Highly Competitive Salary &Benefits

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Senior Systematic Review Analyst - Oxford: Negotiable

Account Director - Digital: Great salary and benefits

Consultant Health Economics - London / Oxford: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe's leading hub for life sciences innovation...